NCT00132626

Study of Brain Imaging With Nuclear Technology in Individuals With Parkinsonian Syndrome

Dynamic SPECT Imaging With [123I]ß-CIT in Patients With Parkinsonism

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 500 (planned)
• Sponsor: Institute for Neurodegenerative Disorders · Academic / Other
• Sex: All
• Age: 35 Years
• Healthy volunteers: Not accepted

Summary

This study assesses dopamine transporter density using single photon emission computed tomography (SPECT) brain imaging with an investigational radiopharmaceutical, \[123I\]ß-CIT, in research participants with Parkinson's disease.

Detailed description

The brain imaging is conducted at the Institute for Neurodegenerative Disorders in New Haven, Connecticut. The imaging procedure occurs over a two day period. After a screening visit, including review of the potential subject's neurological history and a thorough neurologic exam, subjects are injected with \[123I\]ß CIT, an investigational radioactive material that localizes in the brain. Twenty-four hours later study participants return to the Institute for Neurodegenerative Disorders where an investigational scanning procedure is used to obtain SPECT (single photon emission computed tomography) images of the brain.

Conditions

• Parkinson's Disease
• Parkinsonian Syndrome

Interventions

Type	Name	Description
DRUG	[123I]ß-CIT and SPECT imaging

Timeline

• Start date: 1992-09-01
• Completion: 2005-08-01
• First posted: 2005-08-22
• Last updated: 2019-04-03